Northland Capital Partners View on the City - ValiRx


ValiRx (LON:VAL) – CORP: Clinical development update
Market Cap: £4.4m; Current Price: 7.75p

Notification to progress VAL401 clinical trial
 ValiRx issued an update on the clinical development of its cancer treatment drug, VAL401, on the back of receiving approval of the trial protocol in mid-July from the Ethics Committee, covering its clinical site in Tbilisi.
 The group today confirmed that it has received notification of acceptance by all required Regulatory Authorities in Georgia of the protocol and associated documentation for the Phase IIb Clinical Trial of VAL401.
 The approved protocol lists "Tumour progression-free survival" as the primary endpoint.  This will record the length of time between patient screening and progression of the disease, providing a first indication of whether the treatment will be efficacious.  Secondary endpoints include pharmacokinetic measurements; safety and tolerability of the drug; quality of life of the patients and overall survival, providing supporting data on efficacy and drug dosing parameters, which are key to aligning the programme with industry expectations.  The protocol details the dosing and testing schedules to be carried out on each patient for six months treatment, with a maximum of twenty patients to be fully enrolled, with recruitment staggered over a number of months to ensure patient safety.
 Clinical Accelerator, the UK-based clinical trial management organisation engaged by ValiSeek, as previously announced, will be building on their work of achieving this regulatory approval by coordinating the operational and logistical functions of the clinical trial.
NORTHLAND CAPITAL PARTNERS VIEW: This is a significant step and a major milestone in the process for the VAL401 project. Dr Suzanne Dilly, CEO of ValiSeek Limited, commented: “It is very satisfying to have received confirmation from the regulatory experts that the trial has been correctly constructed and that the process of selecting patients for dosing can begin.  After several years of preparation and pre-clinical testing, it is exciting to know that we can expect results to start arriving in the coming months”.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 18 hours ago

2 min read